TABLE 7. Reported cases of notifiable diseases and rates per 100,000 population, by ethnicity*, excluding U.S. territories - - United States, 2016

(Accessible Version: https://wonder.cdc.gov/nndss/static/2016/annual/2016-table7.html)

Disease	Hispa	Hispanic		spanic	Ethnicity not stated	Total
	No.	Rate	No.	Rate	No.	No.
Anthrax	_	_	_	_	_	_
Arboviral diseases						
Chikungunya virus disease	60	0.10	132	0.05	55	247
Eastern equine encephalitis virus disease						
Neuroinvasive	S	S	S	S	S	7
Non-neuroinvasive	_	_	_	_	_	_
Jamestown Canyon virus disease						
Neuroinvasive	S	S	S	S	S	7
Non-neuroinvasive	S	S	S	S	S	8
La Crosse virus disease						
Neuroinvasive	1	0.00	20	0.01	10	31
Non-neuroinvasive	S	S	S	S	S	4
Powassan virus disease						
Neuroinvasive	S	S	S	S	S	21
Non-neuroinvasive	S	S	S	S	S	1
St. Louis encephalitis virus disease						
Neuroinvasive	S	S	S	S	S	7
Non-neuroinvasive	S	S	S	S	S	1
West Nile virus disease						
Neuroinvasive	160	0.28	841	0.32	307	1,308
Non-neuroinvasive	33	0.06	581	0.22	227	841
Western equine encephalitis virus disease						
Neuroinvasive	_	_	_	_	_	_
Non-neuroinvasive	_	_	_	_	_	_
Babesiosis						
Total	72	0.17	1,011	0.54	827	1,910
Confirmed	63	0.15	818	0.44	704	1,585
Probable	9	0.02	193	0.10	123	325
Botulism						
Total	39	0.07	119	0.04	43	201
Foodborne	4	0.01	18	0.01	9	31
Infant [†]	28	2.73	87	2.95	29	144
Other (wound & unspecified)	7	0.01	14	0.01	5	26
Brucellosis	69	0.12	43	0.02	15	127
Campylobacteriosis	7,367	12.82	33,388	12.57	19,365	60,120
Chancroid	S	S	S	S	S	7
Chlamydia trachomatis infection	212,027	368.93	767,700	288.98	618,627	1,598,354
Cholera	S	S	S	S	S	15
Coccidioidomycosis §	1,964	8.04	3,301	3.09	6,564	11,829
Cryptosporidiosis						
Total	1,137	1.98	8,867	3.34	3,449	13,453
Confirmed	827	1.44	5,615	2,11	2,195	8,637
Probable	310	0.54	3,252	1.22	1,254	4,816
Cyclosporiasis	106	0.19	320	0.13	111	537
Dengue virus infections ¶	700	27.0	3.23			
Dengue Dengue	200	0.35	498	0.19	205	903
Dengue-like illness	8	0.55	21	0.19	11	40
Severe dengue	S	0.01 S	S	S	S	10
Diphtheria Diphtheria	3					
Ehrlichiosis and Anaplasmosis	_	_				
Anaplasma phagocytophilum infection	52	0.09	2,557	1.00	1,542	4,151
Ehrlichia chaffeensis infection	28	0.05	918	0.36	431	1,377

TABLE 7. Reported cases of notifiable diseases and rates per 100,000 population, by ethnicity*, excluding U.S. territories - - United States, 2016

(Accessible Version: https://wonder.cdc.gov/nndss/static/2016/annual/2016-table7.html)

	Hisp	Hispanic		spanic	Ethnicity not stated	Total
Disease	No.	Rate	No.	Rate	No.	No.
Ehrlichia ewingii infection	S	S	S	S	S	22
Undetermined ehrlichiosis/anaplasmosis	2	0.00	126	0.05	72	200
Giardiasis	1,063	2.50	8,829	4.18	6,418	16,310
Gonorrhea	54,300	94.48	277,814	104.58	136,400	468,514
Haemophilus influenzae, invasive disease						
All ages, all serotypes	289	0.50	3,118	1.17	1,488	4,895
Age <5 years **						
Serotype b	1	0.02	19	0.13	10	30
Non-b serotype	12	0.23	107	0.72	40	159
Nontypeable	28	0.54	109	0.74	59	196
Unknown serotype	35	0.68	104	0.70	48	187
Hansen's disease	10	0.02	48	0.02	20	78
Hantavirus infection, non-hantavirus pulmonary syndrome	S	S	S	S	S	6
Hantavirus pulmonary syndrome	4	0.01	23	0.01	4	31
Hemolytic uremic syndrome post-diarrheal	36	0.06	228	0.09	43	307
Hepatitis ^{††}						
A, acute	293	0.51	1,232	0.46	482	2,007
B, acute	194	0.34	2,272	0.86	752	3,218
B, perinatal infection ^{§§}	_	_	19	0.32	13	32
C, acute	191	0.35	1,941	0.78	810	2,942
Human immunodeficiency virus diagnoses	8,076	14.05	26,699	10.05	_	34,775
Influenza-associated pediatric mortality ¶¶	20	0.11	49	0.09	13	82
	20	0.11	49	0.09	15	02
Invasive pneumococcal disease	1,119	2.04	10 504	5.19	5,923	17,626
All ages Confirmed		3.04	10,584			
	1,119 S	3.04	10,570 S	5.18	5,914	17,603
Probable **		S 0.46		S 0.20	S 204	23
Age <5 years **	182	0.46	666	0.30	294	1,142
Confirmed	182	5.08	663	5.36	292	1,137
Probable	S	S	S	S	\$	5
Legionellosis	397	0.69	4,506	1.70	1,238	6,141
Leptospirosis	7	0.02	52	0.03	19	78
Listeriosis	87	0.15	564	0.21	135	786
Lyme disease						
Total	546	0.95	13,833	5.23	22,050	36,429
Confirmed	365	0.64	9,666	3.66	16,172	26,203
Probable	181	0.32	4,167	1.58	5,878	10,226
Malaria	59	0.10	1,492	0.56	404	1,955
Measles						
Total	6	0.01	44	0.02	35	85
Indigenous	6	0.01	29	0.01	33	68
Imported	S	S	S	S	S	17
Meningococcal disease						
All serogroups	55	0.10	262	0.10	58	375
Serogroups ACWY	17	0.03	91	0.03	18	126
Serogroup B	6	0.01	67	0.03	13	86
Other serogroups	S	S	S	S	S	21
Unknown serogroup	30	0.05	88	0.03	24	142
Mumps	596	1.04	4,685	1.76	1,088	6,369
Novel Influenza A virus infections	S 2206	S	S 40.350	S 2.00	5	23
Pertussis	2,396	4.17	10,358	3.90	5,218	17,972
Plague	S	S	S	S	S	4
Poliomyelitis, paralytic		_	_		_	
Poliovirus infection, nonparalytic		_	_			_
Psittacosis	S	S	S	S	S	12

TABLE 7. Reported cases of notifiable diseases and rates per 100,000 population, by ethnicity*, excluding U.S. territories - - United States, 2016

(Accessible Version: https://wonder.cdc.gov/nndss/static/2016/annual/2016-table7.html)

	Hispanic		Non-Hispanic		Ethnicity not stated	Total
Disease	No.	Rate	No.	Rate	No.	No.
Q fever						
Total	22	0.04	88	0.03	54	164
Acute	20	0.03	73	0.03	39	132
Chronic	2	0.00	15	0.01	15	32
Rabies						
Human	_	_	_		_	_
Rubella	S	S	S	S	S	1
Rubella, congenital syndrome [†]	S	S	S	S	S	2
Salmonellosis	7,406	12.89	33,064	12.45	13,380	53,850
Severe acute respiratory syndrome-associated coronavirus disease	_	_	_	_	_	_
Shiga toxin-producing Escherichia coli ***	1,274	2.22	4,984	1.88	1,911	8,169
Shigellosis	4,919	8.56	11,539	4.34	4,639	21,097
Smallpox	_	_	_	_	_	_
Spotted fever rickettsiosis						
Total	108	0.19	2,887	1.09	1,274	4,269
Confirmed	4	0.01	93	0.04	57	154
Probable	104	0.18	2,794	1.06	1,217	4,115
Streptococcal toxic shock syndrome	23	0.10	201	0.11	59	283
Syphilis						
Total, all stages ^{†††}	22,694	39.49	58,751	22.12	6,597	88,042
						•
Congenital [†]	187	18.24	407	13.82	34	628
Primary and secondary	6,193	10.78	19,791	7.45	1,830	27,814
Tetanus	4	0.01	20	0.01	10	34
Toxic shock syndrome (other than Streptococcal)	5	0.01	25	0.01	10	40
Trichinellosis	1	0.00	20	0.01	5	26
Tuberculosis	2,601	4.53	6,656	2.51	15	9,272
Tularemia	10	0.02	174	0.07	46	230
Typhoid fever	40	0.07	281	0.11	55	376
Vancomycin-intermediate Staphylococcus aureus	5	0.01	78	0.04	25	108
Vancomycin-resistant Staphylococcus aureus	_				_	
Varicella morbidity	1,559	3.05	5,034	2.41	2,360	8,953
Varicella mortality	U	U	U	U	U	U
Vibriosis						
Total	127	0.22	843	0.32	303	1,273
Confirmed	125	0.22	818	0.31	298	1,241
Probable	2	0.00	25	0.01	5	32
Viral hemorrhagic fevers						
Crimean-Congo hemorrhagic fever virus	_	_	_	_	_	_
Ebola virus	_	_	_	_	_	_
Guanarito virus	_	_	_	_	_	_
Junin virus	_	_	_	_	_	_
Lassa virus	_	_	_	_	_	_
Lujo virus	_	_	_	_	_	_
Machupo virus	_	_	_	_	_	_
Marburg virus	_	_	_	_	_	_
Sabia virus	_	_	_	_	_	_
Yellow fever	S	S	S	S	S	1
Zika virus						
Zika virus disease, congenital †,§§§	18	1.76	5	0.17	7	30
Zika virus disease, congenital	2,079	3.62	1,680	0.63	1,373	5,132
Zika virus infection, congenital †,§§§	16	1.56	3	0.03	26	3,132
7iles vienes infection, con == -:t-1 † 999						

^{—:} No reported cases — The reporting jurisdiction did not submit any cases to CDC. U: Unavailable — The data are unavailable.

S: Suppressed

- * Conditions with <25 cases reported in the year were not broken down by ethnicity.
- † The rate is calculated using population less than 1 year of age.
- § Reportable in <25 states.
- ¶ Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV lgM] and all probable cases (by a single, positive anti-DENV lgM).
- ** The rate is calculated using population less than 5 years of age.
- # Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm.
- §§ The rate is calculated using population less than 2 years of age.
- ¶¶ The rate is calculated using population less than 18 years of age.
- *** Includes Escherichia coli O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.
- +++ Includes syphilis of all stages, including cases where stage of syphilis is not stated.

\$§§ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.

Notes:

- These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS).
 NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
- The list of nationally notifiable infectious diseases and conditions for 2016 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2016" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2015 by CSTE for national surveillance, that were implemented in January 2016, including updated surveillance case definitions for acute hepatitis C and chronic hepatitis C virus infections. 2016 data are reported through June 30, 2017. Publication criteria for the finalized 2016 data are available at /nndss/documents/2016_NNDSS_Publication_Criteria.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS_Data.
- Population estimates for incidence rates are July 1st, 2016 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for July 1, 2011 July 1, 2016, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2016), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states as of June 26, 2017 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2016 mid-year estimates from the U.S. Census Bureau International Data Base accessed on July 24, 2017 at https://www.census.gov/population/international/data/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
- Annual tables for 2016 and later years are available on CDC WONDER.
- Annual summary reports from 1993-2015 are available as published in the MMWR.
- NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).

Suggested Citation:

Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2016 Annual Tables of Infectious Disease Data.
 Atlanta, GA. CDC Division of Health Informatics and Surveillance, 2017. Available at: https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html.

National Notifiable Diseases Surveillance System

Provided by CDC WONDER